10-Q: Nordicus Partners Corporation Reports Increased Net Loss in Q1 2025 Following Orocidin Acquisition

Nordicus Partners Corporation reported a net loss of $258,169 for the quarter ended June 30, 2024, primarily due to increased operating expenses and the acquisition of Orocidin A/S.

Summary

• Nordicus Partners Corporation reported a net loss of $258,169 for the three months ended June 30, 2024, compared to a net loss of $40,296 for the same period in 2023.
• The company's operating expenses increased significantly, reaching $258,169 in Q1 2025, up from $51,589 in Q1 2024.
• This increase was driven by higher officer compensation, professional fees, consulting expenses, and general and administrative costs.
• The company acquired a 95% stake in Orocidin A/S for 38,000,000 shares of common stock, valued at $18,050,000.
• Nordicus also issued 300,000 shares of common stock for consulting services, valued at $150,000.
• As of August 15, 2024, the company had 49,622,248 shares of common stock outstanding.
• The company's cash balance decreased from $49,933 to $26,726 during the quarter.
• The company's accumulated deficit increased to $44,141,696 as of June 30, 2024.

Sentiment

Score: 3

Explanation: The document indicates a negative sentiment due to the significant increase in net loss, rising operating expenses, and a decrease in cash balance. The company's reliance on financing activities and the going concern warning further contribute to the low sentiment score.

Positives

• The company completed the acquisition of a 95% stake in Orocidin A/S, a clinical-stage biopharmaceutical company, which could provide future growth opportunities.
• The company received $60,000 from the exercise of warrants, providing additional capital.

Negatives

• The company experienced a substantial increase in net loss, rising to $258,169 in Q1 2025.
• Operating expenses increased significantly, reaching $258,169, primarily due to higher compensation, professional fees, and consulting expenses.
• The company's cash balance decreased to $26,726, indicating a potential liquidity concern.
• The accumulated deficit increased to $44,141,696, highlighting the company's ongoing financial challenges.

Risks

• The company has a history of losses and an accumulated deficit of $44,141,696, raising concerns about its ability to continue as a going concern.
• The company's minimal revenue and reliance on financing activities to meet obligations pose a significant risk.
• The company's disclosure controls and procedures were deemed not effective at the reasonable assurance level due to limited resources in the finance and accounting functions.
• The company's investment in Mag Mile Capital, Inc. is subject to changes and fluctuations based on their business activities and their ability to trade in the future.

Future Outlook

The company intends to finance operating costs over the next twelve months with existing cash on hand, the private placement of common stock and the exercise of outstanding warrants. The company's ability to continue as a going concern is dependent upon generating profitable operations in the future and/or obtaining the necessary financing.

Management Comments

• Management intends to finance operating costs over the next twelve months with existing cash on hand, the private placement of common stock and the exercise of outstanding warrants.
• Management believes that the company's ability to continue as a going concern is dependent upon generating profitable operations in the future and/or obtaining the necessary financing.

Industry Context

The company operates in the financial consulting sector, with a focus on assisting Nordic companies in the pharmaceutical, life sciences, and healthcare industries to establish themselves in the U.S. market. The acquisition of Orocidin A/S, a biopharmaceutical company, aligns with this industry focus and could provide future growth opportunities.

Comparison to Industry Standards

• The company's lack of revenue and significant net loss are concerning when compared to industry standards for financial consulting firms.
• The company's reliance on stock issuance and warrant exercises for funding is not typical for established companies in the sector.
• The acquisition of Orocidin A/S is a significant strategic move, but its impact on the company's financial performance remains to be seen.
• The company's financial performance is significantly worse than comparable companies in the financial consulting and biopharmaceutical sectors, which typically have established revenue streams and positive cash flows.

Management Changes

Corporate Governance

Related Party Transactions

• The company had related party transactions with GK Partners, including warrant exercises and stock issuances.
• The company paid legal fees to an affiliate of Bennett Yankowitz, the chief financial officer and director.
• A related party forgave a payable of $13,886, which was credited to additional paid-in capital.

Stakeholder Impact

• Shareholders are negatively impacted by the increased net loss and the going concern warning.
• Employees may be concerned about the company's financial stability.
• Customers may be impacted by the company's ability to provide services if financial challenges persist.
• Creditors may be concerned about the company's ability to repay its liabilities.

Next Steps

• The company intends to improve its disclosure controls and procedures.
• The company will seek to generate profitable operations.
• The company will explore options for obtaining necessary financing.

Key Dates

Keywords

Nordicus Partners, Orocidin A/S, Acquisition, Net Loss, Operating Expenses, Financial Consulting, Biopharmaceutical, Stock Issuance, Warrants, Mag Mile Capital